MAM
PSTX

Martingale Asset Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Martingale Asset Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,116
Closed -$73K – 893
2022
Q1 		$73K Sell
16,116
-7,600
-32% -$34.3K ﹤0.01% 797
2021
Q4 		$162K Buy
23,716
+8,101
+52% +$55.2K ﹤0.01% 804
2021
Q3 		$114K Buy
+15,615
New +$134K ﹤0.01% 836

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Martingale Asset Management's PSTX Position: Q2 2022 in Review

Martingale Asset Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2022, closing a stake of 16,116 shares — an estimated $73K sold.

Martingale Asset Management first reported a position in PSTX in Q3 2021 and held it in 3 quarters. The position peaked at $162K in Q4 2021. 56 funds tracked by Wall St. Rank hold PSTX as of Q2 2022.

  • Martingale Asset Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Martingale Asset Management sold 16,116 Poseida Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $73K.
  • Martingale Asset Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Martingale Asset Management's Poseida Therapeutics, Inc. Common Stock position peaked at $162K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Martingale Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.